Imidazopyrimidines, potent inhibitors of p38 MAP kinase

被引：267

作者：

Rupert, KC ^{[1
]}

Henry, JR ^{[1
]}

Dodd, JH ^{[1
]}

Wadsworth, SA ^{[1
]}

Cavender, DE ^{[1
]}

Olini, GC ^{[1
]}

Fahmy, B ^{[1
]}

Siekierka, JJ ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, LLC, Drug Discovery, Raritan, NJ 08869 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 03期

关键词：

D O I：

10.1016/S0960-894X(02)01020-X

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：347 / 350

页数：4

共 50 条

[21] MAP kinase p38 inhibitors:: Clinical results and an intimate look at their interactions with p38α protein
Lee, MR
Dominguez, C
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (25) : 2979 - 2994
[22] Synthesis and biological evaluation of BIRB 796 analogs as potent inhibitors of p38 MAP kinase.
Swinamer, AD
Capolino, A
Cirillo, PF
Gilmore, T
Graham, A
Hickey, E
Moriak, M
Madwed, J
Moss, N
Nelson, R
Pargellis, C
Regan, J
Torcellini, C
Tsang, M
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U59 - U60
[23] Design, synthesis and biological evaluations of novel substituted imidazooxazoles as potent p38 MAP kinase inhibitors
Liu, YB
Ashwell, MA
Ali, SM
Antonenko, V
Graceffa, R
Harris, M
Kaselj, M
Kelleher, E
Liu, J
O'Donnell, M
Selliah, R
Tandon, M
Vensel, D
Wrona, W
Lapierre, JM
Bresciano, K
Caserta, K
Chan, H
Gannett, T
Jones, S
Leydon, P
Mcdonald, S
Naper, A
Saraswat, L
Tyler, A
Warren, M
Zhu, S
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U2723 - U2723
[24] P38 kinase inhibitors
Lloyd, AW
DRUG DISCOVERY TODAY, 2000, 5 (12) : 570 - 571
[25] Inhibitors of p38 kinase
Hanson, GJ
EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (07) : 729 - 733
[26] Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors
Sarma, Rituparna
Sinha, Sharat
Ravikumar, Muttineni
Kumar, Madala Kishore
Mahmood, S. K.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (12) : 2870 - 2876
[27] Process Research and Development for Heterocyclic p38 MAP Kinase Inhibitors
Thiel, Oliver R.
Achmatowicz, Michal
Milburn, Robert M.
SYNLETT, 2012, (11) : 1564 - 1574
[28] 'Reverse' α-ketoamide-based p38 MAP kinase inhibitors
Montalban, Antonio Garrido
Boman, Erik
Chang, Chau-Dung
Ceide, Susana Conde
Dahl, Russell
Dalesandro, David
Delaet, Nancy G. J.
Erb, Eric
Gibbs, Andrew
Kahl, Jeff
Kessler, Linda
Lundstroem, Jan
Miller, Stephen
Nakanishi, Hiroshi
Roberts, Ed
Saiah, Eddine
Sullivan, Robert
Wang, Zhijun
Larson, Christopher J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5456 - 5459
[29] Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase
Hammach, Abdelhakim
Barbosa, Antonio
Gaenzler, Faith Corbo
Fadra, Tazmeen
Goldberg, Daniel
Hao, Ming-Hong
Kroe, Rachel R.
Liu, Pingrong
Qian, Kevin C.
Ralph, Mark
Sarko, Christopher
Soleymanzadeh, Fariba
Moss, Nell
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) : 6316 - 6320
[30] Allosteric and slow binding inhibitors of p38 MAP kinase.
Regan, J
Breitfelder, S
Cirillo, P
Gilmore, T
Graham, A
Hickey, E
Madwed, J
Moriak, M
Moss, N
Pargellis, C
Proto, A
Tong, L
Torcellini, C
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U683 - U683

← 1 2 3 4 5 →